Management of "unfavourable" carcinoma of unknown primary site: Synthesis of recent literature

Critical Reviews in Oncology/Hematology

Volumn 84, Issue 2, 2012, Pages 213-223

  Amela, Eric Yaovi ^a   Lauridant Philippin, Géraldine ^a   Cousin, Sophie ^a   Ryckewaert, Thomas ^a   Adenis, Antoine ^a,b   Penel, Nicolas ^a,c  

^a CENTRE OSCAR LAMBRET   (France)

^b UNIVERSITÉ CATHOLIQUE DE LILLE   (France)

^c Research Unit (EA2694)   (France)

Author keywords

Carcinoma of unknown primary; Chemotherapy; Prognosis; Review

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; MEGESTROL ACETATE; MITOMYCIN C; NAVELBINE; OXALIPLATIN; PACLITAXEL;

CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER OF UNKNOWN PRIMARY SITE; CANCER PROGNOSIS; HUMAN; MAINTENANCE THERAPY; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; REVIEW; SALVAGE THERAPY; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS, UNKNOWN PRIMARY; PROGNOSIS;

EID: 84867840604     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2012.03.003     Document Type: Review

References (56)

1. Hainsworth J.D., Greco F.A. Treatment of patients with cancer of an unknown primary site. N Engl J Med 1993, 329:257-263.
2. Bugat R., Bataillard A., Lesimple T., et al. Summary of the standards, options and recommendations for the management of patients with carcinoma of unknwn primary site (2002). Br J Cancer 2003, 89:S559-S566.
3. Fizazi K., Greco F.A., Pavlidis N., Pentheroudakis G. Cancers of unknown primary site: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011, 22(Suppl 6). ESMO Guidelines Working Group, vi64-8.
4. Randen M., Rutqvist E., Johansson H. Cancer patients without knwon primary: incidence and survival trend in Sweden. Acta Oncol 2009, 48:915-920.
5. Greco F.A., Olien K., Erlander M., et al. Cancer of unknown primary: progress in the search for improved and rapid diagnosis leading toward superior patient outcomes. Ann Oncol 2012, 23:298-304.
6. Horlings H.M., Van Laar R.K., Kerst J.M., et al. Gene expression profiling to identify the histogenetic origin of metasatic adenocarcinomas of unknown primary. J Clin Oncol 2008, 26:4435-4441.
7. Varadahachary G.R., Raber M.N., Matamoros A., Abbruzzese J.L. Carcinoma of unknown primary wit a colon-cancer profile-changing paradigm and emerging definitions. Lancet Oncol 2008, 9:596-598.
8. Varadhachary G.R., Talantov D., Raber M.V., et al. Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. J Clin Oncol 2008, 26:4442-4448.
9. Pavlidis N., Fizazi K. Carcinoma of unknown primary (CUP). Crit Rev Oncol Hematol 2009, 69:271-278.
10. Pavlidis N., Fizazi K. Carcinoma of unknown primary (CUP). Crit Rev Oncol Hematol 2005, 54:243-250.
11. Van der Gaast A., Verweij J., Planting A.S., Hop W.C., Stoter G. Simple prognostic model to predict survival in patients with undifferentiated carcinoma of unknown primary site. J Clin Oncol 1995, 3:1720-1725.
12. Culine S., Kramar A., Saghatchian M., et al. Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol 2002, 20:4679-4683.
13. Seve P., Ray-Coquard I., Trillet-Lenoir V., et al. Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with unknown primary site. Cancer 2006, 107:2698-2705.
14. Penel N., Négrier S., Ray-Coquard I., et al. Development and validation of a bedside score to predict early death in cancer of unknown primary patients. PLOS One 2009, 4(8):e6483.
15. Ferté C., Penel N., Bonneterre J., Adenis A. Individual life-expectancy estimation using validated prognostic score for patients with cancer of unknown primary. Oncology 2010, 78:87-93.
16. Gross-Goupil M., Fourcade A., Blot A., et al. A randomized trial of cisplatin with or without gemcitabine in patients with carcinoma of an unknown primary and without poor prognostic factors: results of the GEFCAPI02 trial. Ann Oncol 2008, 19(Suppl 9):vii248.
17. Culine S., Lhortolary A., Voigt J.J., et al. Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site:results of a randomized phase II study-trial for the French study group on carcinomas of unknown primary (GEFCAPI 01). J Clin Oncol 2003, 21:3479-3482.
18. Palmeri S., Lorusso V., Palmeri L., et al. Cisplatin and gemcitabine with either vinorelebine or paclitaxel in the treatment of carcinomas of unknown primary. Cancer 2006, 107:2898-2905.
19. Asserhorn L., Norman A.R., Cunningham D., et al. A randomised study of protracted venous infusion of 5-fluorourcil (5-FU) with or without bolus mitomycin C (MMC) in patients with carcinoma of unknown primary. Eur J Cancer 2003, 39:1121-1128.
20. Dowell J.E., Garrett A.M., Shyr Y., Johnson D.H., Hande K.R. A randomized phase II trial in patients with carcinoma of an unknown primary site. Cancer 2001, 91:592-597.
21. Falkson C.I., Cohen G.L., Mitomycin C Epirubicin and cisplatin versus mitomycin C alone as therapy for carcinoma of unknown primary origin. Oncology 1998, 55:116-121.
22. Huebner G., Link H., Kohne C.H., et al. Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with andeo- or undifferentiated carcinoma of unknown primary: a randomized prospective phase II trial. Br J Cancer 2008, 100:44-49.
23. Culine S., Fabbro M., Ychou M., Romieu G., Cupissol D., Pujol H. Chemotherapy in carcinoma of unknown primary site: a high-dose intensity policy. Ann Oncol 1999, 1à:569-575.
24. Hainsworth J.D., Burris H.A., Calvert S.W., et al. Gemcitabine in the second-line therapy of patients with carcinoma of unknown primary site: a phase II trial of the Minnie Pearl cancer research network. Cancer Invest 2001, 19:335-339.
25. Hainsworth J.D., Spigel D.R., Raefsky E.L., et al. Combination chemotherapy with gemcitabine in patients with previously treated carcinoma of unknown primary site. Cancer 2005, 104:1992-1997.
26. Hainsworth J.D., Spigel D.R., Farley C., Thompson D.S., Shipley D.L., Greco A. Phase IIx trial of Bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl cancer research network. J Clin Oncol 2007, 25:1747-1752.
27. Hainsworth J.D., Spigel D.R., Burris H.A., et al. Oxaliplatin and capecitabine in the treatment of patients with recurrent or refractory carcinoma of unknown primary site - a phase 2 trial of the Sarah Cannon Oncology Research Consortium. Cancer 2010, 116:2448-2454.
28. Moller A.K., Pedersen K.D., Abildgaard J., Petersen B.L., Dauggard G Capecitabine and oxaliplatin as second-line treatment in patients with carcinoma of unknown primary site. Acta Oncol 2010, 49:431-435.
29. Park Y.H., Ryoo B.Y., Choi S.J., Yang S.H., Kim H.T. A phase II study of paclitaxel plus cisplatin chemotherapy in an unfavourable group of patients with cancer of unknown primary site. Jpn J Clin Oncol 2004, 34:681-685.
30. Mukai H., Katsumata N., Ando M., Watanabe T. Safety and efficacy of a combination of docetaxel and cisplatin in patients with unknown primary cancer. Am J Clin Oncol 2010, 33:32-35.
31. Greco F.A., Erland J.B., Morrissey L.H., et al. Carcinoma of unknown primary site: phase II trials with docetaxel plus cisplatin or carboplatin. Ann Oncol 2000, 11:211-215.
32. Voog E., Merrouche Y., Trillet-Lenoir V., et al. Multicentric phase II study of cisplatin and etoposide in patients with metastatic carcinoma of unknown primary. Am J Clin Oncol 2000, 23:614-616.
33. Moller A.K., Pedensen K.D., Gothelf A., Daugaard G Paclitaxel, cisplatin and gemcitabine in treatment of carcinomas of unknown primary site, a phase II study. Acta Oncol 2010, 49:423-430.
34. Parnis F.X., Olver I.N., Kotasek D., et al. Phase II study of epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) for carcinoma of unknown primary site. Ann Oncol 2000, 11:883-884.
35. Balana C., Manzano J.L., Moreno I., et al. A phase II study of cisplatin, etoposide and gemcitabine in an unfavourable group of patients with carcinoma of unknown primary site. Ann Oncol 2003, 14:1425-1429.
36. Guardiola E., Pivot X., Tchicknavorian X., et al. Combination of cisplatin-doxorubicincyclophosphamide in adenocarcinoma of unknown primary site. A phase II trial. Am J Clin Oncol 2001, 24:372-375.
37. McDonald A.G., Nicolson M.C., Samuel L.M., Hutcheon A.W., Ahmed F.Y. A phase II study of mitomycin C, cisplatin and continuous infusion 5-fluorouracil (MCF) in the treatment of patients with carcinoma of unknown primary site. Br J Cancer 2002, 86:1238-1242.
38. Briasoulis E., Klofonos H., Bafaloukos D., et al. Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic cooperative oncology group study. J Clin Oncol 2000, 18:3101-3107.
39. El-Rayes B.F., Shields A.F., Zalupski M., et al. A phase II study of carboplatin and paclitaxel in adenocarcinoma of unknown primary. Am J Clin Oncol 2005, 28:152-156.
40. Berry W., Elkory M., O'Rourke M., Kahn M., Asmar L. Results of a phase II study with weekly paclitaxel plus carboplatin in advanced carcinoma of unknown primary origin: a reasonable regimen for the community-based clinic?. Cancer Invest 2007, 25:27-31.
41. Pentheroudakis G., Briasoulis E., Kalofonos H.P., et al. Docetaxel and carboplatin chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: a multicentre Hellenic cooperative oncology phase II study. Acta Oncol 2008, 47:1148-1155.
42. Pittman K.B., Olver I.N., Koczwara B., et al. Gemcitabine and carboplatin in carcinoma of unknown primary site: a phase 2 adelaide cancer trials and education collaborative study. Br J Cancer 2002 2006, 95(10):1309-1313.
43. Warner E., Goel R., Chang J., et al. A multicentre phase II study of carboplatin and prolonged oral etoposide in the treatment of cancer of unknown primary site (CUPS). Br J Cancer 1998, 77(12):2376-2380.
44. Yonemori K., Ando M., Yunokawa M., et al. Irinotecan plus carboplatin for patients with carcinoma of unknown primary. Br J Cancer 2009, 100:50-55.
45. Greco F.A., Burris H.A., Litchy S., et al. Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl cancer research network study. J Clin Oncol 2002, 20:1651-1656.
46. Hainsworth J.D., Erlnd J.B., Kalman L.A., Schreeder M.T., Greco F.A. Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide. J Clin Oncol 1997, 15:2385-2393.
47. Schneider B.J., El-Rayes B., Muler J.H., et al. Phase II trial of carboplatin, gemcitabine, and capeticabine in patients with carcinoma of unknown primary site. Cancer 2007, 110:770-775.
48. Piga A., Nortilli R., Cetto G.L., et al. Carboplatin, doxorubicin and etoposide in the treatment of tumours of unknown primary site. Br J Cancer 2004, 90:1898-1904.
49. Hainsworth J.D., Spigel D.R., Thompson D.S., et al. Paclitaxel/carboplatin plus bevacizumab/erloitinib in the first-line treatment of patients with carcinoma of unknown primary site. Oncologist 2009, 14:1189-1197.
50. Schuette K., Folprecht G., Kretzschmar A., et al. Phase II trial of capecitabine and oxaliplatin in patients with adenocarcinoma and undifferentiated carcinoma of unknown primary. Onkologie 2009, 32:162-166.
51. Briasoulis E., Fountzilas G., Bamias A., et al. Multicenter phase II trial of irinotecan plus oxaliplatin [IROX regimen] in patients with poor-prognosi cancer of unknown primary: a Hellenic cooperative oncology group study. Cancer Chemother Pharmacol 2008, 62:277-284.
52. Pouessel D., Culine S., Becht C., et al. Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site. Cancer 2004, 100:1257-1261.
53. Culine S., Fabbro M., Ychou M., Romieu G., Cupissol D., Pinguet F Alternative bimonthly cycles of doxorubicin, cyclophosphamide, and etoposide, cisplatin with hematopoietic growth factor support in patients with carcinoma of unknown primary site. Cancer 2002, 94:840-846.
54. Culine S., Fabbro M., Ychou M., Romieu G., Cupissol D., Pujol H. Chemotherapy in carcinomas of unknown primary site: high-dose intensity policy. Ann Oncol 1999, 10:569-575.
55. Greco F.A., Rodriguez G.I., Shaffer D.W., et al. Carcinoma of unknown primary site: sequential treatment with paclitaxel/carboplatin/etoposide and gemcitabine/irinotecan: a minnie pearl cancer research network phase II trial. Oncologist 2004, 9:644-652.
56. Hainsworth J.D., Spigel D.R., Clark B.L., et al. Paclitaxel/carboplatin/etoposide versus gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a randomized, phase III Sarah Cannon Oncology Research Consortium Trial. Cancer J 2010, 16:70-75.